Trends in Pharmacological Sciences

Article	Citations
Subscription and Copyright Information	850
Shearing of surface mucin saps tumor cell strength	541
Subscription and Copyright Information	395
Structural asymmetry in FGF23 signaling	219
Advisory Board and Contents	214
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	195
Subscription and Copyright Information	182
Subscription and Copyright Information	164
Muscarinic receptors: from clinic to bench to clinic	153
Subscription and Copyright Information	150
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	146
Peptides as a therapeutic strategy against Klebsiella pneumoniae	139
Swinging the SWI/SNF complexes for cancer therapy	121
Compstatins: the dawn of clinical C3-targeted complement inhibition	121
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	121
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	116
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	111
Targeting complement in neurodegeneration: challenges, risks, and strategies	106
Structural pharmacology and mechanisms of GLP-1R signaling	105
Therapeutic inhibition of ferroptosis in neurodegenerative disease	105
Direct in vivo CAR T cell engineering	94
Nemolizumab (Nemluvio®) for prurigo nodularis	86
Advisory Board and Contents	86
Ribosome-directed cancer therapies: the tip of the iceberg?	85
Phenotypic approaches for CNS drugs	84

A deep dive into degrader-induced protein-protein interfaces	80
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	79
Advisory Board and Contents	78
A perspective on psychedelic teratogenicity: the utility of zebrafish models	77
Advisory Board and Contents	76
Optogenetic engineering for precision cancer immunotherapy	70
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	69
A smart hospital-driven approach to precision pharmacovigilance	69
Leveraging human microbiomes for disease prediction and treatment	68
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	68
siRNA drug Leqvio (inclisiran) to lower cholesterol	67
HSV-1 as a gene delivery platform for cancer gene therapy	66
Engineering ACE2 decoy receptors to combat viral escapability	64
Close to a year in TIPS’ saddle – I am optimistic	64
Genetically engineered loaded extracellular vesicles for drug delivery	64
Emerging strategies for beta cell transplantation to treat diabetes	64
Subscription and Copyright Information	61
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	58
Thriving as members of under-represented groups in pharmacology-related careers	56
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	55
Advisory Board and Contents	54
Bimetallic nanoadjuvants for cancer vaccines	54
Lipoxygenases in chronic liver diseases: current insights and future perspectives	53
Subscription and Copyright Information	53
Suzetrigine for moderate to severe acute pain	52
Could dexmedetomidine be repurposed as a glymphatic enhancer?	51
Mentoring future science leaders to thrive	47
Now you serine, now you don't	46
Piezo1: structural pharmacology and mechanotransduction mechanisms	45
Emerging approaches to induce immune tolerance to therapeutic proteins	45
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	45
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	44
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	44
Advancing non-destructive analysis of 3D printed medicines	42
The structure, function, and pharmacology of MRGPRs	41
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	41
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
The road less traveled: activating an oncogenic kinase	40
Advisory Board and Contents	40
The promise of targeted protein degradation approaches	38
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	38
Salt-inducible kinases: new players in pulmonary arterial hypertension?	38
Promising neuroimmune targets and drugs for CNS diseases	37
A novel function of the M2 muscarinic receptor	37
Subscription and Copyright Information	36
The end of the beginning in understanding SLC22 polyspecificity	36
Validation of agent-based models of surface receptor oligomerisation	35
Advisory Board and Contents	35
Beyond G protein and arrestin: GRK2-biased β₂AR signaling	35

Frizzleds act as dynamic pharmacological entities	34
Tackling microbial iron homeostasis: novel antimicrobial strategies	33
Decoding pseudouridine: an emerging target for therapeutic development	33
Targeting intracellular protein–protein interactions with macrocyclic peptides	33
Protein acylations in cancer immunity: effects and therapeutic opportunities	33
Monkeypox: potential vaccine development strategies	33
Nanocarriers for oral delivery of biologics: small carriers for big payloads	33
Metabolic regulation in normal and leukemic stem cells	32
BTK inhibitors: past, present, and future	32
Advisory Board and Contents	32
Circulating tumor cells in precision medicine: challenges and opportunities	31
Demographic diversity in platelet function and response to antiplatelet therapy	31
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	31
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	31
Development of PROTACs using computational approaches	30
Recent advances in generative biology for biotherapeutic discovery	29
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	29
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	29
Subscription and Copyright Information	29
Engineered antibody fusion proteins for targeted disease therapy	28
GPR35: from enigma to therapeutic target	28
Eflornithine for treatment of high-risk neuroblastoma	28
Targeting plasma membrane cholesterol as a novel anticancer therapy	27
Targeting sensory neuron GPCRs for peripheral neuropathic pain	27
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	27
Subscription and Copyright Information	27
Biologics and cardiac disease: challenges and opportunities	27
Subscription and Copyright Information	27
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	25
High-power screening (HPS) empowered by DNA-encoded libraries	25
Subscription and Copyright Information	25
A novel anticancer pharmacological agent targeting mitochondrial complex I	25
Tackling chronic kidney disease in diabetic patients with finerenone	25
Boosting CAR-T cell therapy through vaccine synergy	24
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	24
Harnessing associative learning paradigms to optimize drug treatment	24
Recent advancements in vaccine research and development	23
Subscription and Copyright Information	23
Neutrophil extracellular traps in wound healing	23
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	23
Visceral obesity and HFpEF: targets and therapeutic opportunities	23
Taming PRMT5–adaptor protein interactions	22
Circadian biology to advance therapeutics for mood disorders	22
Multitargeting neuroimmune pathways: novel candidates for chronic pain relief	22
The ABCs of psychedelics: a preclinical roadmap for drug discovery	22
Challenges and opportunities associated with rare-variant pharmacogenomics	22
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	21
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery	21
Potential for targeting small heat shock protein modifications	20
GPCR-dependent and -independent arrestin signaling	20
GABAA receptors as targets for treating affective and cognitive symptoms of depression	20
Advisory Board and Contents	20
NLRP3 and pyroptosis blockers for treating inflammatory diseases	20
Subscription and Copyright Information	19
Odorant receptors as potential drug targets	19
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Glymphatic-stagnated edema induced by traumatic brain injury	18
Advisory Board and Contents	18
Malolactone strikes: K-Ras-G12D's Achilles' heel	18
Targeted protein degrader development for cancer: advances, challenges, and opportunities	18
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18
The structure and function of YTHDF epitranscriptomic m6A readers	18
Subscription and Copyright Information	18
Learning from natural design for local anesthetic delivery	17
Advancing small-molecule drug discovery by encoded dual-display technologies	17
Hans Jürg Schatzmann (1924–2021)	17
Advisory Board and Contents	17
Bridging the gap in neuropsychiatric translational research	17
Glaucoma: neuroprotection with NAD-based therapeutic interventions	17
Emerging epigenetic insights into aging mechanisms and interventions	16
Mitochondrial dynamics proteins as emerging drug targets	16
Advisory Board and Contents	16
Electroceuticals: emerging applications beyond the nervous system and excitable tissues	16
Celiac disease: mechanisms and emerging therapeutics	16
Thapsigargin: key to new host-directed coronavirus antivirals?	16
Leveraging non-enzymatic functions of LSD1 for novel therapeutics	16
Advisory Board and Contents	15
Structural perspective of class B1 GPCR signaling	15
Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics	15

NET-targeted therapy: effects, limitations, and potential strategies to enhance treatment efficacy	15
Fluorescent RNAs: new opportunities for drug discovery	15
Harnessing deep learning for enhanced ligand docking	15
Subscription and Copyright Information	14
Reactive chemistry for covalent probe and therapeutic development	14
Multiple hERG channel blocking pathways: implications for macromolecules	14
Subtyping for pancreatic cancer precision therapy	14
Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation	14
Advisory Board and Contents	14
Targeting glycosylation to enhance tumor immunotherapy	14
Safety of medicines and vaccines – building next generation capability	14
Advisory Board and Contents	14
Apart, together: reflections on the COVID-19 pandemic	14
Advisory Board and Contents	14
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	14
Engineering extracellular vesicles for diagnosis and therapy	13
Endometriosis: cannabidiol therapy for symptom relief	13
Targeting chromosomal instability and aneuploidy in cancer	13
At last: the mitochondrial pyruvate carrier structure revealed!	13
TNIK’s emerging role in cancer, metabolism, and age-related diseases	13
Isoform-selective targeting of PI3K: time to consider new opportunities?	13
Subscription and Copyright Information	13
Current landscape of preclinical models of diabetic cardiomyopathy	13
Nanodelivery of cGAS-STING activators for tumor immunotherapy	13
Advisory Board and Contents	12
Targeting sialylation to treat central nervous system diseases	12
Recent breakthroughs and future directions in drugging aquaporins	12
Targeting galectin-3 in inflammatory and fibrotic diseases	12
A mechanism for ligand-dependent activation of AHR	12
Present and future of microglial pharmacology	12
Advisory Board and Contents	11
Photoswitchable allosteric and dualsteric ligands in GPCR pharmacology	11
Subscription and Copyright Information	11
IRAK4: potential therapeutic target for airway disease exacerbations	11
Advisory Board and Contents	11
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research	11
Unifying mechanism behind the onset of acquired epilepsy	10
Heterobifunctional small molecules to modulate RNA function	10
18F-Flurpiridaz PET for imaging of myocardial ischemia	10
Casimersen for the treatment of Duchenne muscular dystrophy	10
Emerging mechanisms of psilocybin-induced neuroplasticity	10
Therapeutic targeting of exportin-1 beyond nuclear export	10
Paving the way for designing drugs targeting TMEM16A	10
Neuron–tumor crosstalk fuels small cell lung cancer	10
Structural snapshot of a β-arrestin-biased receptor	9
Fezolinetant for menopausal hot flashes and night sweats	9
Subscription and Copyright Information	9
Repurposing trifluoperazine for glioblastoma treatment	9
Mutations in muscle-type creatine kinase impact HIV prevention	9
Advisory Board and Contents	9
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities	8
Subscription and Copyright Information	8
The structure and function of olfactory receptors	8
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain	8
Targeting TRPM channels for cerebral ischemia–reperfusion injury	8
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads	8
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	8
VMAT structures reveal exciting targets for drug development	8
Beyond the blood–brain barrier: the fate of transcytosed therapeutics	8
Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development	8
A quick guide to networking for scientists	8
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	8
Giving ERK a jERK from the endosome	8
Targeting neurological abnormalities in lysosomal storage diseases	8
PPAR agonists for the treatment of neuroinflammatory diseases	8
Emerging paradigms and recent progress in targeting ErbB in cancers	8
Current views on N-glycolylneuraminic acid in therapeutic recombinant proteins	7
Gut-derived brain T cells modulate behavior via IFN-γ	7
Some assembly required: a single-RNA vaccine against enterovirus-D68	7
The potential of long noncoding RNA therapies	7
ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics	7
Cholesterol – the devil you know; ceramide – the devil you don’t	7
PSA inhibitors for contraception: insights from prostate cancer	7
Subscription and Copyright Information	6
Data and AI-driven synthetic binding protein discovery	6
Potentiation of GPCR signaling by ATP and sugar monophosphates	6
Advances in cell therapy: progress and challenges in hematological and solid tumors	6
Design and development of glucocorticoid receptor modulators	6
A decoy mutant ACE2 designed to reduce COVID-19	6
Leveraging spatial omics for the development of precision sarcoma treatments	6
Emerging mechanisms and therapeutics in inflammatory muscle diseases	6
Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment	6
Hypothalamic AMPK as a possible target for energy balance-related diseases	6
Targeting solute carriers to modulate receptor–ligand interactions	6
Glycine: a long-sought novel ligand for GPR158	6
Chromosome-scale genomes throw light on plant drug biosynthesis	6
Subscription and Copyright Information	6
Regulation of drug-metabolizing enzymes by sex-related hormones: clinical implications for transgender medicine	6
Human carbonic anhydrase modulators: the past, present, and future	6
Targeting Fks1 proteins for novel antifungal drug discovery	6
Targeting mitochondrial dynamics and redox regulation in cardiovascular diseases	5
The future of neuroimmunology research for CNS disease therapeutics	5
Shining light on parvalbumin interneuron plasticity	5
Next-generation isoform-selective fibroblast growth factor receptor inhibitors	5
Pharmacogenomics in treatment of depression and psychosis: an update	5